Literature DB >> 22833838

A dyspnea patient with abnormal prolonged prothrombin time and activated partial thromboplstin time, but without bleeding symptoms.

Zhi-de Hu, Bing Gu, An-Mei Deng.   

Abstract

A patient with erythrocytosis secondary to chronic obstructive pulmonary disease (COPD) was admitted to hospital because of dyspnea. The coagulation tests revealed abnormal prolonged prothrombin time (PT) and activated partial thromboplstin time (APTT), however, it could not be explained by the patient's medical history or physical signs of coagulation disorder. High hematocrit (Hct), which leads to reduced plasma-to-anticoagulant rate and increased final plasma anticoagulant concentration, was identified as the reason for false prolongation of PT and APTT.

Entities:  

Keywords:  APTT; Hct; PT; erythrocytosis; plasma-to-anticoagulant rate

Year:  2012        PMID: 22833838      PMCID: PMC3378226          DOI: 10.3978/j.issn.2072-1439.2011.09.07

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  6 in total

1.  Interference of blood cell lysis on routine coagulation testing.

Authors:  Giuseppe Lippi; Martina Montagnana; Gian Luca Salvagno; Gian Cesare Guidi
Journal:  Arch Pathol Lab Med       Date:  2006-02       Impact factor: 5.534

Review 2.  How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults.

Authors:  Arif H Kamal; Ayalew Tefferi; Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2007-07       Impact factor: 7.616

3.  Quality control in coagulation testing.

Authors:  Mario Plebani; Maria Colomba Sanzari; Lorena Zardo
Journal:  Semin Thromb Hemost       Date:  2008-12-15       Impact factor: 4.180

4.  Iron stores and coagulation parameters in patients with hypoxemic polycythemia secondary to chronic obstructive pulmonary disease: the effect of phlebotomies.

Authors:  J A Martinez; C C Guerra; L E Nery; J R Jardim
Journal:  Sao Paulo Med J       Date:  1997 Mar-Apr       Impact factor: 1.044

Review 5.  Prothrombin time and partial thromboplastin time assay considerations.

Authors:  Valerie L Ng
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

6.  Preanalytical conditions that affect coagulation testing, including hormonal status and therapy.

Authors:  M Blombäck; B A Konkle; M J Manco-Johnson; K Bremme; M Hellgren; R Kaaja
Journal:  J Thromb Haemost       Date:  2007-01-12       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.